Vivoryon Therapeutics NV (VVY) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.838x

Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has a cash flow conversion efficiency ratio of -0.838x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.96 Million ≈ $-4.63 Million USD) by net assets (€4.73 Million ≈ $5.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VVY equity financing ratio to measure how much of total assets are equity-financed.

Vivoryon Therapeutics NV - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Vivoryon Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vivoryon Therapeutics NV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Vivoryon Therapeutics NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vivoryon Therapeutics NV ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Widodo Makmur Unggas Tbk PT JK:WMUU	-0.001x
Widodo Makmur Perkasa PT JK:WMPP	-0.003x
Domiki Kritis S.A. AT:DOMIK	0.028x
RTA Laboratuvarlari Biyolojik IS:RTALB	0.010x
Omesti Bhd KLSE:9008	-0.218x
Harn Engineering Solutions Public Company Limited BK:HARN	0.006x
Petrolia SE OL:PSE	0.238x
Megawin Technology Co Ltd TWO:3122	-0.003x

Annual Cash Flow Conversion Efficiency for Vivoryon Therapeutics NV (2011–2025)

The table below shows the annual cash flow conversion efficiency of Vivoryon Therapeutics NV from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Vivoryon Therapeutics NV.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€4.73 Million ≈ $5.53 Million	€-8.46 Million ≈ $-9.88 Million	-1.789x	+26.49%
2024-12-31	€7.88 Million ≈ $9.21 Million	€-19.17 Million ≈ $-22.42 Million	-2.433x	-196.88%
2023-12-31	€26.28 Million ≈ $30.73 Million	€-21.54 Million ≈ $-25.18 Million	-0.820x	+0.32%
2022-12-31	€26.51 Million ≈ $30.99 Million	€-21.79 Million ≈ $-25.48 Million	-0.822x	-20.93%
2021-12-31	€16.56 Million ≈ $19.36 Million	€-11.26 Million ≈ $-13.16 Million	-0.680x	-27.23%
2020-12-31	€26.22 Million ≈ $30.66 Million	€-14.01 Million ≈ $-16.38 Million	-0.534x	-96.41%
2019-12-31	€42.66 Million ≈ $49.88 Million	€-11.61 Million ≈ $-13.57 Million	-0.272x	+95.22%
2018-12-31	€1.23K ≈ $1.44K	€-6.99K ≈ $-8.18K	-5.686x	-318.73%
2017-12-31	€8.92K ≈ $10.43K	€-12.12K ≈ $-14.17K	-1.358x	-67.77%
2016-12-31	€16.38K ≈ $19.15K	€-13.26K ≈ $-15.50K	-0.809x	-7.50%
2015-12-31	€16.13K ≈ $18.86K	€-12.15K ≈ $-14.20K	-0.753x	-13.56%
2014-12-31	€15.97K ≈ $18.67K	€-10.59K ≈ $-12.38K	-0.663x	-132.85%
2013-12-31	€-4.22 Million ≈ $-4.94 Million	€-8.53 Million ≈ $-9.97 Million	2.018x	+189.94%
2012-12-31	€5.37 Million ≈ $6.27 Million	€-12.04 Million ≈ $-14.08 Million	-2.244x	-134.20%
2011-12-31	€14.95 Million ≈ $17.47 Million	€-14.32 Million ≈ $-16.74 Million	-0.958x	--

About Vivoryon Therapeutics NV

AS:VVY Netherlands Biotechnology

Market Cap

$44.32 Million

€37.91 Million EUR

Market Cap Rank

#22905 Global

#84 in Netherlands

Share Price

€1.28

Change (1 day)

-8.57%

52-Week Range

€1.00 - €1.72

All Time High

€26.50